Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’
暂无分享,去创建一个
J. Blay | S. Aamdal | R. Sciot | A. Italiano | J. Šufliarský | P. Rutkowski | M. Debiec‐Rychter | H. Gelderblom | P. Reichardt | S. Stacchiotti | S. Strauss | S. Collette | P. Schöffski | A. Wozniak | L. Lindner | S. Bauer | B. Kasper | J. Blay | S. Marréaud | M. Leahy | L. Albiges | A. Anthoney | I. Hennig | B. Zakotnik | T. Raveloarivahy | W. V. D. van der Graaf | T. van Cann | M. Leahy | M. Debiec-Rychter